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ABSTRACT 
Introduction 
Sepsis, and in particular, severe sepsis, remains a major cause of death in children 
worldwide. One of the areas where the burden of sepsis is keenly felt is in the paediatric 
intensive care unit (PICU) setting, contributing significantly to childhood mortality. 
Fungal organisms have emerged as a major organism contributing to nosocomial sepsis in 
PICU.  No local data regarding nosocomial fungal sepsis in the non-neonatal, PICU 
population exists regarding this matter. This study describes the characteristics of patients 
with nosocomial fungal sepsis in the PICU at South Africa’s largest hospital Chris Hani 
Baragwanath Academic Hospital (CHBAH).  
 
Methods 
This study was a retrospective review of patient records. All patients aged 0-16 years   
admitted to the PICU at Chris Hani Baragwanath Academic Hospital (CHBAH) from 
January 2008 through December 2011 were assessed. A total of seventeen patients who 
developed nosocomial fungal sepsis were included in this study. 
 
Results 
The incidence of candidaemia was reported to be 3.2 per 100 cases. The major age group 
affected by nosocomial fungal sepsis was the under one age group. The most common 
diagnoses on admission were lower respiratory tract infection (LRTI) followed by 
haematology-oncology and acute gastroenteritis cases. ICU	  factors	  found	  to	  commonly	  co-­‐exist	   with	   proven	   nosocomial	   fungal	   sepsis	   were	   presence	   of	   a	   central venous 
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catheter (100%), mechanical ventilation (82%), arterial line (70%), and systemic 
corticosteroid use (47%). The penicillin class was the most common antimicrobial that 
patients were found to be on at the time of nosocomial sepsis. The most common fungal 
organism as a cause for nosocomial sepsis was C. parapsilosis rather than C. albicans. 
Furthermore, the majority of this study’s isolates were susceptible to voriconazole rather 
the current empiric antifungal of choice, namely fluconazole.  
 
Conclusion 
The presence of central venous catheters, arterial lines, mechanical ventilation and 
systemic corticosteroid use is common in paediatric patients with nosocomial fungal 
sepsis. However, this study was unable to determine statistically significant factors 
associated with fungal sepsis in a tertiary PICU due to the surprisingly small number of 
cases (n=35) detected over a four-year period. This perhaps represents the most striking 
finding of the study together with a concerning pattern of fluconazole resistance (14%) 
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1.1 Background  
Sepsis, and in particular, severe sepsis, remains a major cause of death in children 
worldwide. (1-3) Sepsis is defined as a systemic inflammatory response syndrome (SIRS) 
in the presence of or as a result of a suspected or proven infection.  (4) This definition, 
including the definitions for the continuum of sepsis was defined for the paediatric 
population by the International Pediatric Sepsis Consensus Conference in 2002.  These 
include definitions for infection, SIRS, sepsis, severe sepsis and septic shock, which are 
summarized in appendix A.  
The World Health Organization (WHO) reported infectious diseases as the number one 
killer of children under the age of five years, causing 68% of deaths in this age group in 
2008.  (5)  One of the areas where the burden of sepsis is keenly felt is in the paediatric 
intensive care unit (PICU) setting, contributing significantly to childhood mortality. (6,7) 
A Japanese study reported PICU mortality of 28% in patients diagnosed with septic 
shock between 2007 and 2009. An Italian study reported a staggering 51% mortality rate 
among children with septic shock in the PICU.  (8) Likewise, high mortality rates due to 
septic shock were also reported in Pakistan, affecting approximately a third (32,8%) of 
the population admitted to the PICU from 2007 through 2008. (9) 
With such a significant burden to childhood mortality, extensive research is aimed at 
improving the diagnosis and management of sepsis.  (1,4,10,11) However despite these 
efforts, studies continue to demonstrate a rise in the incidence of severe sepsis. A 1995 
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population-based study investigating severe sepsis reported an incidence in excess of 
42,000 new cases among American children. (3) Further epidemiological data from the 
United States (US) reported a staggering increase in the incidence of sepsis from 82.7 per 
100,000 population to nearly 240.4 per 100,000 population over a 21-year period 
between 1979 and 2000.  (6)  
Not only does severe sepsis impact dramatically on childhood morbidity and mortality, it 
also poses a significant healthcare problem due to the extensive usage of healthcare 
resources. The attributable annual cost to the US health-care system in 1995 was 1.97 
billion US dollars, which more than doubled to 4.8 billion US dollars per annum over the 
subsequent ten year period. (12) With sepsis attributing heavily to childhood mortality 
both in developed and developing countries, as well as heavily burdening health-care 
costs, extensive research is required in determining the cause, pathophysiology and 
management of sepsis in PICU. (10) 	  
1.2 Microbial aetiology of sepsis in the PICU 
The three most common microbial groups causing sepsis in the PICU are Gram-positive 
bacteria, Gram-negative bacteria and fungi.  (13-15) In the mid 1990’s the most common 
infecting organisms were Staphylococcus species, however by 2005 it had become 
apparent that Gram-negative organisms were responsible for a large proportion of severe 
sepsis cases in the PICU.  (3,14,15) The most common Gram-negative pathogens were 
Pseudamonas aeruginosa and Enterococcus faecalis in a Japanese and Brazilian study, 
respectively.  (14,15) This evolving face of microbial epidemiology was also noted in 
North America where a significant increase in organisms other than bacteria, such as 
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fungal infections was noted over a 22-year period. Candida species (responsible for the 
vast majority of fungal infections) has been reported as the fourth most common 
pathogen responsible for nosocomial (hospital-acquired) sepsis.  (6,16) 
 
1.3 Nosocomial fungal sepsis  
A few decades ago, fungi were uncommon nosocomial pathogens.  (17) However, since 
1979 fungi have emerged as important pathogenic organisms among patients with 
nosocomial sepsis.  (18,19) The last two decades of the twentieth century saw a 
staggering 207% increase in new cases of fungal sepsis.  (6) Italian researchers found that 
the incidence of candidaemia had more than doubled among critically ill patients around 
the turn of the century.  (20) 
Among fungal organisms, Candida species are the most common organisms responsible 
for fungal bloodstream infections (BSI). (16,21) Overall, they are the fourth most 
common isolate in nosocomial BSI and the third most common cause of nosocomial BSI 
in critically ill patients.  (16,22,23) Consistent with the overall increase in fungal 
infections, the incidence of nosocomial candidaemia has also risen rapidly over the past 
two decades.  (6,24-26) A five-fold  increase of candidaemia from 0.06 to 0.3 per 1,000 
inpatients was observed between 2000 and 2009 in the US. (25) Of note, the rate of 
nosocomial candidaemia among the non-neonatal paediatric population doubled during a 
9 year period between 1997 and 2005.  (24)  
Candida species can be broadly classified into two groups namely Candida albicans 
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(CA) and the non-albicans Candida (NAC). Over recent years, despite the emergence of 
NAC species causing disease, CA remains the most common fungus to cause 
bloodstream infections in the paediatric population, accounting for 40-60% of cases.  
(24,27-32) 
2.0 BASIC MYCOLOGY OF CANDIDA 
The genus Candida is classified as follows: 
• Kingdom: Fungus 
• Phylum: Ascomycota 
• Subphylum: Saccharomycotina 
• Class: Saccharomycetes 
• Order: Saccaromycetales and 
• Family: Saccharomycetaceaea.  (33) 
Candida colonies appear cream to yellow macroscopically and are typically grown on 
Sabouraud dextrose agar. Colony texture may differ according to the species and may be 
smooth, dry or wrinkled. Growth occurs as blastoconidia, which are spherical to oval 
shaped budding cells.  (34) Certain morphological features help in distinguishing between 
Candida species such as branch-like extensions from the budding cell, otherwise known 
as true hyphae or pseudohyphae.  (35) True hyphae and/or pseudohyphae are diagnostic 
features of C. albicans. In contrast, C. glabrata lack the ability to grow hyphae and exist 
as ovoid blastoconidia.  (34,35) Other distinguishing features include the size of 
blastoconidia of which C. glabrata measures the smallest (1-4 µm) and the largest species 
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C. albicans (4–6 µm) and C. tropicalis (4–8 µm).  (36)  
ˆThe Candida genus contains over 150 species of which a minority (13 species) have 
been implicated in the pathogenesis of disease in humans. The most common of these are 
C. albicans and among the NAC species, C. glabrata, C. krusei, C. parapsilosis, and C. 
tropicalis.  (21,24,28) Furthermore, approximately two thirds of Candida species are 
unable to grow at temperatures around 37°C rendering them unable to successfully dwell 
and colonize human hosts. (35)  
Candida species usually exist as human commensals as part of the normal flora found on 
the skin, oropharyngeal cavity, gastrointestinal tract and vaginal tract.  (37) Candida can 
also be found on other mammals, birds, arthropods, fish, plants, as well as soil, water and 
airborne particles.  (38) Pathogenicity of Candida is initiated once the immune defenses 
of the host have been compromised and/or following events resulting in a disruption or 
imbalance of the host’s normal commensal flora.  (37) 
2.1 PATHOGENESIS OF CANDIDA SPECIES 
Broadly speaking, the pathogenicity of Candida species can be attributed to two primary 
virulence factors: 
1. adherence and biofilm formation on host tissue and medical devices  
2. host tissue-damage by the production of hydrolytic enzymes such as 
phospholipases, proteases and haemolysins. 	  (34,39): 
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2.1.1 Adherence and biofilm formation 
Adherence to host tissue is the initial step for Candida species to ensure persistence of 
the organism within the host, which ultimately leads to the establishment of disease. 
Specific cell wall proteins (adhesins), allow Candida to adhere to human tissue as well as 
to other surfaces such as medical devices.  (34)  These adhesin proteins are encoded by 
different gene families, depending on the specific Candida species.  (34) 
C. glabrata’s adhesins are encoded by the gene family EPA (epithelial adhesin) and have 
the ability to adapt to a wide variety of environmental conditions.  (40) The advantage 
conferred to the organisms by this adaptability results in an improved ability to adhere to, 
and subsequently colonise host tissue. 
Once adherence to the host tissue has been established, Candida species undergo the 
processes of cell division and proliferation, in order to produce a population of 
microorganisms incorporated within an extracellular matrix (biofilm).  (41) The biofilm, 
by virtue of its solid matrix, is able to resist the host immune responses and minimize the 
penetration of antifungal substances.  (42) Thus the biofilm contributes significantly to 
the outcome of patients who have established fungal disease. The attributable mortality 
rate in patients with bloodstream infections caused by biofilm-positive organisms 
compared to those without biofilm formation was reported to be as high as 30%.  (43)  
The formation of a biofilm is influenced both by the Candida species, as well as the 
environment to which the organism is exposed.  (41) In particular, C. albicans isolates 
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produce quantitatively and qualitatively superior biofilm matrices in substrate similar to 
indwelling devices, when compared to NAC species such as C. parapsilosis, C. glabrata 
and C. tropicalis.  (44) In contrast, C. albicans produced the least amount of biofilm on 
Sabouraud dextrose broth (SDB) containing 8% glucose (similar to milieu of patients 
receiving total parenteral nutrition via a central venous catheter) compared to C.tropicalis 
followed by C. parapsilosis.  (43,45) Furthermore, C. glabrata was reported as the most 
frequent organism forming biofilms on indwelling catheters in the presence of urine.  (46)  
2.1.2 Host Tissue Damage By Hydrolytic Enzyme Production 
Host tissue destruction may be expedited by the release of hydrolytic enzymes produced 
by Candida species. The most frequently encountered enzymes are secreted aspartyl 
proteinases, phospholipases, lipases and haemolysins. (34) 
 
Secreted aspartyl proteinases contribute to pathogenicity by digesting mucosal 
membranes and molecules of the host immune system.  (34) Phospholipases and lipases 
are involved in the hydrolysis of fatty acids and triacylglycerol components of host cells.  
(34) C. albicans strains, in particular, show significant extracellular phospholipase 
activity which contributes to the enhanced virulence of this species.  (47) 	  
2.2 RISK FACTORS FOR NOSOCOMIAL CANDIDA BLOODSTREAM 
INFECTION 
Knowledge of the population at risk for nosocomial Candida BSI is imperative for 
further preventative measures and empiric treatment of the disease. Risk factors can be 
broadly grouped into defects of host’s immunity and effects from the external 
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environment increasing the probability of acquiring a Candida BSI. 
2.2.1 Host factors 
Once host immune defences have been compromised, Candida species, which formerly 
existed as human commensals, are able to invade, populate and exert its detrimental 
effects on the host. Paediatric immunocompromised states described in the literature 
include immunodeficiency disease, malignancy, neutropaenia, bone marrow 
transplantation, undergoing surgery, critical illness, prematurity, very-low-birth-weight 
and congenital anomalies.  (28)  
In particular, South Africa still carries the highest burden of people living with HIV (6,1 
million of  the global 35,3 million global estimates) at the end of 2012. (48) Of the 6,1 
million affected individuals in South Africa, children from zero to fourteen years of age 
account for 6,7% (410,000) of South Africa’s total. (49) Data from the Chris Hani 
Baragwanath Hospital paediatric medical wards showed an approximate 10-fold increase 
in the prevalence of HIV infected individuals from 1992 to 1997.  (50) Furthermore, in 
the same period the study reported a longer length of stay, higher readmission rate and a 
staggering 42% increase in the in-hospital mortality of patients infected with HIV 
compared to the non-HIV population.  (50)  
With regards to PICU and HIV, a first-world study in the late 1980’s showed case fatality 
rates of up to 84% in HIV-infected children requiring intensive care.  (51) Offering 
intensive care to this population in a resource poor country such as South Africa remains 
a difficult decision.  (52) However, South African studies that were conducted in 2003 
and 2009 have seen a decline in mortality rate of 30% and an increased survival rate up to 
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64% in the HIV-infected admissions to PICU.  (52,53) A possible reason for the 
improved survival rate could be attributed to the rollout of Highly Active Antiretroviral 
Treatment to HIV-infected children.  (54) With prolonged survival of this HIV-infected 
population, fungal infections have begun to emerge as a key organism in causing 
morbidity and mortality in the immunocompromised host.  (28,55)  
Candida species remain one of the most common opportunistic infections in children 
infected with HIV.  (55,56)In the late 90’s, a European study among HIV infected 
individuals reported C. albicans as the most frequently isolated pathogen, followed by C. 
tropicalis and C. glabrata.   (57) It is the response of the host’s immune system, which 
determines the extent of Candida pathogenicity. Manifestations of Candida infection 
have been described as benign oral mucosal overgrowth to widespread haematogenous 
dissemination causing organ compromise in the host.  (55)  
Invasive fungal infections are also an important cause of morbidity and mortality among 
neutropenic patients. (58) A 2015 retrospective analysis in Turkey showed a 3.1 fold 
increase in mortality among patients with neutropenia and Candidaemia.  (59) Radiation, 
chemotherapy, bone marrow failure, or the replacement of hematopoietic cells in the 
bone marrow by malignant cells, are the main causes of neutropenia.  (60) Neutropenia in 
itself is a significant risk factor for the development of systemic Candida disease.  (60) 
The main portal of entry is via the alimentary tract and when disrupted, invasion to the 
main bloodstream ensues.  (60) Candida infection manifestations range from 
oropharyngeal candidiasis, oesophageal candidiasis, candidaemia, acute disseminated 
candidiasis or chronic disseminated candidiasis.  (60) 
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2.2.2 Environmental factors 
Environmental risk factors described are as follows: 
• endotracheal intubation with mechanical ventilation 
• central venous lines 
• arterial lines 
• urinary catheter 
• hypoalbuminaemia 
• male gender 
• neutropaenia 
• total parenteral nutrition (TPN) 
• prolonged ICU stay 
• broad-spectrum antibiotics 
• bacterial infections 
• corticosteroids 
• blood transfusions and  
• peritoneal or haemodialysis.  (24,26-28,59) 
Specifically, two factors were independently associated with the development of 
candidaemia in the PICU, namely the presence of a central venous catheter (CVC) and 
the receipt of a glycopeptide antibiotic (Vancomycin) or antimicrobial activity against 
anaerobic organisms for more than three days.  (27) A study in 2015 showed a 20.5 fold 
increase in mortality due to failure of removal of a CVC in patients with candidaemia.  
(59) 
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The first line of defense in the human body against infections is the presence of physical 
barriers, such as the skin and other epithelial surfaces, to prevent the entry of foreign 
micro-organisms. CVC’s penetrate these natural barriers of the body and allow for the 
invasion of Candida species into otherwise sterile sites.  (28,31) CVC placement for three 
days or longer, has been associated with a three-fold risk for developing disseminated 
candidiasis in children with candidaemia.  (61)   
The glycopeptide antibiotic Vancomycin has activity against anaerobic bacteria in the 
gastrointestinal tract.  (27) Under normal circumstances anaerobic gut flora contribute to 
the host’s defense mechanisms by minimizing the growth of potentially pathogenic 
organisms such as Candida species. By eliminating this protective mechanism by the 
usage of antimicrobials, the probability for Candida species to colonize the 
gastrointestinal tract, and then subsequently invade the host, rises.  (27) 
Host and environmental factors frequently co-exist, especially in the PICU setting where 
critically ill patients with varying degrees of immunosuppression are exposed to multiple 
invasive procedures.  
2.3 DIAGNOSIS OF CANDIDA BLOODSTREAM INFECTION 
The definitive diagnosis of Candida BSI has represented a daunting challenge to both the 
clinician and the microbiologist.  (62) Traditionally, the gold standard for the diagnosis 
of fungaemia has been isolation of the organism by blood culture from a normally sterile 
site.  (62,63) Identification of yeasts is by carbohydrate assimilation and/or fermentation 
together with their macroscopic and microscopic morphologic features after growth on 
specialized culture media.  (63) Disappointingly, the sensitivity of blood culture has 
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remained at a paltry 50%.  This sensitivity is further compromised by technical errors 
such as use of non-sterile sites, insufficient blood sample volume and inadequate 
incubation time.  Samples drawn from a non-sterile site make it virtually impossible to 
distinguish between colonization and invasive disease. Furthermore, due to the sluggish 
growth of yeast, the timeous initiation of antifungal therapy may be delayed, so much so, 
that the decision to start antifungal therapy is often an empiric one. (62,63) 
Due to the poor yield of blood culture for the diagnosis of fungaemia, other tests using 
non-culture based tools have been developed and are currently used in conjunction with 
conventional blood culture methods. These tests include the (1,3)- β-D-glucan assay 
(BDG), fungal DNA using polymerase chain reactions and antibody assays.  
Detection of a fungal cell wall component namely (1,3)- β-D-glucan (BDG) has been 
approved by the Food and Drug Administration of the US (FDA) as a diagnostic adjunct 
for invasive fungal disease including Candida species.  (62) Being a fungal cell wall 
constituent, BDG can be used to detect the presence of most fungal species except for 
zygomycetes and Cryptococcus  (63) The benefits of BDG as a biomarker when 
excluding invasive Candida infection was demonstrated by its negative predictive value 
of almost 99%.  (64) However, false-positives are also common and measurement of 
BDG may be affected by exposure to glucan-containing gauze, intravenous 
administration of albumin, haemodialysis or Gram-positive bacteraemia such as 
Streptococcus.  (62,65) It has been reported that certain Gram-positive bacteria such as 
Streptococcus and Alcaligenes also produce glucan-like polymers, which may falsely 
elevate the BDG levels.  (66) 
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A rapid and more sensitive test using the polymerase chain reaction (PCR) method for the 
identification of Candida is being utilized more frequently in the PICU setting.  (67) 
Isolates can be identified within 7 hours when compared to conventional phenotypic 
methods taking up to 48 to 72 hours long.  (67)  
Detection of antibodies against Candida albicans germ tubes has also been described.  
(63) However most critically ill patients  may be  unable to mount an adequate immune 
response, thus rendering tests utilizing the detection of antibodies as potentially 
ineffective. More specific markers of fungal components such as the cell wall and 
cytoplasmic antigens have provided an alternative means of providing a diagnosis.  (63) 
Attention has also been drawn to other potential biomarkers associated with the presence 
of fungal disease. The presence of thrombocytopaenia has been used as a marker for 
sepsis in critically ill patients.  (68) Studies in the neonatal population have shown an 
association between thrombocytopaenia and fungal sepsis.  (69-71) However scarce data 
exists for the non-neonatal paediatric population and further investigation into this 
phenomenon may be helpful in identifying patients at high risk of having a Candida BSI.  
 
2.4 TREATMENT OF CANDIDA BLOODSTREAM INFECTION 
Treatment of Candida BSI relies on timeous administration of antifungal therapy based 
on the polyene, azole or echinocandin families.  (32,72) Choice of antifungal therapy 
must be based on knowledge of local epidemiology, organism susceptibility, exposure to 
previous antifungal agents and the patient’s clinical status.  
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The polyene antifungal (Amphotericin B) has been the most commonly used agent in the 
treatment of candidaemia, owing to its broad-spectrum activity.  (73-75) However, the 
conventional Amphotericin B deoxycholate is known for its dose-limited toxicity, of 
which nephrotoxicity has been most frequently described.  (74,76) Amphotericin B is a 
fungicidal agent disrupting the cell membrane by binding to ergosterol. Subsequently 
pores are formed in the membrane causing it to become leaky and depolarize.  (77) In an 
attempt to improve the therapeutic index and provide a safer alternative, three forms of 
the agent were developed. These lipid-containing forms are amphotericin B lipid 
complex, liposomal amphotericin B, and amphotericin B colloidal dispersion.  (74) 
Currently, the high cost of these lipid-containing forms does not make them widely 
accessible in a resource-limited setting such as the Chris Hani Baragwanath Academic 
Hospital (CHBAH). However as the cost declines the newer forms of Amphotericin B 
will most likely play a significant role in the treatment of Candida BSI.  (74) Despite its 
broad-spectrum activity and minimal intrinsic and acquired resistance, owing to its dose-
limited toxicity, the polyene class is still limited in treatment when compared to the 
azoles and echinocandins.  (77) 
The azoles (fluconazole, voriconazole) are also a widely used antifungal drug with no 
nephrotoxic effects as compared to Amphotericin B.  (77) This class inhibits cytochrome 
P-450 dependent enzyme C-14α-demethylase. This enzyme is essential in the 
conversion of lanosterol to ergosterol, which forms part of the fungal cell membrane.  
(77) Despite its’ low cytotoxicity, this class also displays significant limitations, namely:  
the development of resistance with prolonged use and drug-drug interactions, specifically 
drugs metabolized by the cytochrome P-450 isoenzyme.  (78,79) 
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The echinocandins (caspofungin) are an emerging class of antifungal agents. FDA 
approval for Caspofungin was granted in 2001. Echinocandins inhibit cell wall synthesis 
by inhibiting the enzyme BDG-synthase, an essential component for wall synthesis.  (78) 
Caspofungin was found to be as effective as amphotericin B, while exhibiting fewer 
drug-related side effects and a 72% favourable response over the standard amphotericin B 
group in the treatment of invasive candidiasis.  (79,80) 
Caspofungin, fluconazole, an amphotericin B formulation or combination therapy have 
been suggested by recent guidelines for the treatment of invasive candidiasis.  (72) Other 
studies have suggested caspofungin and amphotericin B as first line therapies in 
neutropenic and critically ill patients where fluconazole-resistant Candida isolates may 
predominate.  (79) However, patient therapy needs to be targeted and individualized to 
provide the most cost effective, therapeutic and least toxic treatment to the critically ill 
paediatric patient.  (72,79) 
 
2.5 MORTALITY ASSOCIATED WITH CANDIDA BSI 
Mortality due to candidaemia in hospitalised patients remains high.  (81-83) Mortality 
rates of approximately 60% were reported in observational studies, owing to nosocomial 
C. albicans sepsis.  (24,75,82,83) This could be due to C. albican’s  enhanced virulence 
by destroying host tissue through phospholipases.  (47) However, non- albicans species 
are seen to be on the rise as significant causes of mortality, especially in the premature 
and immunosuppressed populations.  (25,84)  
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This mortality is found to be increased due to other environmental factors shown in 
recent studies investigating risk factors for mortality in candidaemic pediatric patients.  
(59,85) A 2016 Brazilian study found increase in mortality in patients with sepsis, septic 
shock, acute renal insufficiency, mechanical ventilation and dialysis.  (85) In 2015, a 
Turkish study showed a significant result of a 23-fold increase in mortality of patients 
with candidaemia, (more than 3 months of age) where failure to remove CVC’s were 
noted.  (59) 
Furthermore, mortality rates were affected by the timing of initiation of antifungal 
therapy. An American study carried out from 2002 to 2005 showed a ten percent increase 
in mortality rate for every day that antifungal therapy was delayed.  (29) Consequences of 
failure to treat with antifungal therapy resulted in more than 25% of deaths over a four 
year period. (83) 
 
2.6 WHAT THIS STUDY ADDS 
This study aims to describe the characteristics of patients with nosocomial fungal sepsis 
in the PICU at South Africa’s largest hospital CHBAH. There is overwhelming literature 
regarding fungal sepsis and the neonatal population however, a paucity of studies exists 
among the older pediatric population requiring intensive care. With the emergence of 
fungal sepsis as one of the leading causes of mortality in the PICU, an understanding of 
the risk factors may aid in the development of future guidelines for the empiric treatment 
of fungal nosocomial sepsis in the South African setting. This study is the first to be 
undertaken among a predominantly black non-neonatal paediatric population at a hospital 
serving a community with a high burden of HIV disease.  
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CHAPTER TWO 
2.1 OBJECTIVES 
The objective for this study was to describe the characteristics of patients who had 
developed a nosocomial fungal bloodstream infection in the PICU at the Chris Hani 
Baragwanath Academic Hospital. 
 
The specific objectives were to:  
 1. Determine the incidence of fungal infections in the PICU 
2. Describe the demographics of patients with nosocomial fungal bloodstream infections 
in the paediatric intensive care unit 
3. Describe the PICU factors associated with nosocomial fungal bloodstream infections.  
2.2 METHODS 
2.2.1 Study design 
This study was a retrospective descriptive study. 
 
2.2.2 Study population 
All patients aged 0-16 years, admitted to the PICU at Chris Hani Baragwanath Academic 
Hospital (CHBAH) from January 2008 through December 2011. CHBAH is an academic 
tertiary hospital situated in Gauteng province with 3200 beds of which 408 are paediatric 
beds. It currently serves Soweto and surrounding communities. The PICU consists of an 
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8-bed critical care unit that has an estimate of 360 annual admissions. All patients 
admitted to the PICU were identified using the PICU admissions database.  
 
2.2.3 Definition of Case Patients 
Case patients were patients who had developed a nosocomial fungal BSI. Nosocomial 
fungal BSI was defined by proven fungal species yielded on blood culture that was taken 
at least 48 hours after admission to PICU, in addition to the presence of SIRS. Case 
patients were identified from the microbiology database at the National Health 
Laboratory Services (NHLS). Once patients were identified, databases were retrieved 
from the PICU records department situated at the CHBAH. 
 
Patients with incomplete records and infected simultaneously with fungal and non-fungal 
organisms on blood culture were excluded. 
 
2.2.4 Data Collection 
All blood cultures, which deemed a positive fungal growth between 2008 and 2011 were 
identified through an extensive search performed by an NHLS accredited data analyst. 
Names of patients were identified and files were retrieved from the CHBAH ICU records 
department.  
A data collection tool, RedCap was used to collect patient data. (Appendix B). This data 
sheet included four sections namely: patient demographics, background, laboratory 
results and PICU-related factors.  
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Demographics dealt with patient sex and age at time of diagnosis. Background factors 
included primary condition, pre-ICU major operation (any surgery requiring general 
anaesthesia) and HIV status. Laboratory data collected included organism yielded on 
blood culture and drug susceptibility at the time of SIRS. ICU-related factors included 
devices (CVC, urinary catheter, arterial-line, intercostal chest drain, endotracheal tube 
and tracheostomy devices), dialysis (haemo-dialysis and peritoneal dialysis), class of 
antimicrobial therapy used for more than 24 hours, receipt of TPN, immunosuppressant 
usage and three or more blood product transfusions. ICU-related factors were selected by 
review of previous studies with similar objectives.  
 
2.2.5 Statistical Analysis 
For descriptive purposes, means, medians, ranges (min-max) and proportions 
(percentages) were reported for categorical variables.  
 
2.2.6 Ethical considerations 
Ethics approval was obtained from the Committee for Research in Human Subjects at the 
University of the Witwatersrand (Medical) and the Medical Advisory Committee of the 
Chris Hani Baragwanath Academic Hospital. Permission to conduct research was 
obtained from the director of the PICU at CHBAH. The National Health Laboratory 
Service granted permission to access patient data from the central database. 
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CHAPTER THREE  
3. RESULTS 
3.1 Incidence 
There were a total of 1085 admissions to the CHBAH PICU from January 2008 to 
December 2011. Thirty-five patients (3%) with positive fungal blood cultures were 
identified during the four year period. Fourteen of the 35 files were missing from the data 
department and four patients did not fit the inclusion criteria. Thus, 17 cases were 
included in the study. 
 
3.2 Characteristics 
The demographics of the 17 eligible patients are summarized in table 3.1. The gender 
distribution was similar with 53% female (9/17) and 47% males (8/17). Patient age 
ranged from day 1 of life to 11 years 5 months with a median age of 10 months. Age 
distribution was compared among male and female groups. Males presenting at PICU had 
a higher median age (1 year 6 months) while females presented at a younger age (4 
months). Among the patients with HIV results available (n=12, 70%), the vast majority 
was HIV negative (92%) with only one patient with confirmed fungal sepsis testing HIV 
positive. The remaining 5 patients (30%) did not have an HIV result available at the time 
of their PICU admissions.. The time from admission up to the time where fungal sepsis 
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Age distribution (All patients)*  
Male age distribution* 


































* Median (range: min-max)  
 
 
3.3 Admission Diagnoses 
The most common group of admission diagnoses was lower respiratory tract 
infections with nearly a third (29%) of patients admitted for either 
bronchopneumonia or a lobar pneumonia. A summary of the admission diagnoses is 
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Acute lymphoblastic leukaemia (ALL) 













Congenital cardiac defect 
 
Urogenital 
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3.3 Fungal isolates 
The most common isolates from the paediatric intensive care unit were Candida 
parapsilosis (n=9), followed by Candida albicans (n=7).  





Susceptibilities were reported for 15 of the 17 (88%) fungal isolates. No 
susceptibilities were specified for C. lusitaniae and one of the C. albicans isolates.  
The remaining fifteen  organisms’ susceptibility patterns are summarized in Table 
3.3. Seventy five percent (3/6) of the C. albicans group was susceptible to 
fluconazole ,an additional 16% (1/6) to voriconazole and all reported isolates 
remained sensitive to Amphotericin B (6/7). One of the six (17%) C. albicans 
isolates was resistant to both fluconazole and voriconazole. In the C. parapsilosis 
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remained sensitive to Amphotericin B.  One of the nine (11%) C. parapsilosiss 
isolates was resistant to both fluconazole and voriconazole..  
 
Table 3.3 Reported Susceptibility to Antifungals 
 Organism	  (n)	   Fluconazole	  Sensitive	   Voriconazole	  Sensitive	   Amphotericin	  Sensitive	  	   	  	   	  	   	  
	  
C.	  
parapsilosis	  (9)	  	  
	  2	  (22%)	   	  6	  (67%)	   	  9	  (100%)	   	   	   	  	  
	  
C.	  albicans	  (6)	   	  4	  (67%)	   	  5	  (83%)	   	  6(100%)	   	   	   	  	  
 
3.5 ICU related factors 
All of the patients with nosocomial fungal sepsis were found to have central venous 
catheters in situ (100%). Fourteen of the 17 patients received mechanical ventilation 
(82%). The most common antimicrobial received during the time of onset of sepsis 
was penicillin (71%).  The other ICU related factors and subsequent findings on 
steroid use, TPN and other associated factors are summarized in table 3.4, which was 
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Table 3.4 ICU related factors in patients who developed nosocomial fungal sepsis 
 
 
ICU related factors n (%) 
 










Arterial line 12 (70%) 
 
Steroids 8 (47%) 
 
Total parenteral nutrition 6 (35%) 
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CHAPTER FOUR 
4. 0 Discussion 
Local studies regarding epidemiology and factors associated with nosocomial fungal 
sepsis in the PICU is scarce. Nosocomial fungal sepsis is becoming an increasingly 
important subject of research owing to its high contribution to morbidity and mortality.  
 
The aim of this study was to determine the incidence of nosocomial fungal sepsis, and to 
describe the demographics and PICU related factors of these affected patients. 
Knowledge regarding the trends of fungal organism growth and its associated factors are 
beneficial to the clinician when initiating treatment. Results from the analysis are 
discussed in this chapter, in light of other published studies.  
 
4.1 Incidence 
The incidence of candidaemia in the CHBAH PICU is 3.2 cases per 100 admissions. 
Thirty-five candidaemias were diagnosed in 1,085 patients (32.3 episodes per 1,000 ICU 
patients). These results are comparable to developed countries where the incidence lies 
between 1,7 to 10 episodes per 100,000 patients. (86) Although South Africa is 
considered to be an economically growing country, it is still considered a developing 
country where healthcare resources remain a scarce commodity especially in the 
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4.2 Patient Demographics 
The median age of fungal bloodstream infections was 10 months, which is similar to the 
findings of PICU studies conducted in Taiwan and Egypt, which both reported a majority 
of cases of fungal infection among the  under-one age group  (31,86).This could possibly 
be due to the vulnerability of this younger age group to serious diseases. These findings 
are in contrast to two other studies, which found most subjects with candidaemia to be 
over one-year of age. (87,88) The first study, performed in India (2011) found most 
patients in the 1 to 15 year old age group.  (88) The second study, a case-control study in 
Turkey (2010) investigating the risk factors for candida in PICU reported a median age of 
7.5 yrs.  (87) 
 
Gender distribution was fairly similar with an insignificantly higher percentage of 
females (53%). These findings are different to other studies from developing and 
developed countries. Male predominance was found in the Egyptian PICU study where 
56.7% were male and 43.3% female. (86) An American study also showed a slightly 
higher male predominance (55.4%) in candidaemia infections  (25).  
 
Despite the high HIV burden in South Africa, 65% of cases were HIV negative and only 
one child (six percent) was confirmed to be HIV positive, thus the association between 
HIV and fungal sepsis could not be explored further. Kumar et al found 3.3% (7/210) 
association of HIV positive children and fungal sepsis.  (88)  
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Of concern however, is the high proportion of subjects with unknown HIV status (29%). 
Three of the five patients had a medical diagnosis and the remaining two were admitted 
from the trauma unit, having both been involved in pedestrian vehicle accidents. At Chris 
Hani Baragwanath Academic Hospital, paediatric medical cases are referred from the 
general medical intake ward (ward 36). Here, patients are stabilized and relevant 
serological and radiological tests ordered prior to PICU referral. According to the 
hospital’s paediatric policy, ward 36 is a crucial area where the patients’ HIV status is 
either confirmed or investigated if unknown status. If the mother reveals that she is HIV 
positive during history-taking,  an HIV-PCR is done on the patient provided the patient is 
under 18 months of age. If the patient is 18 months or older a confirmatory ELISA is 
taken and results followed up by the attending unit on call. However, if the mother 
reveals that she has been tested HIV negative, a confirmatory ELISA is done on the 
mother only and not on the patient. The three medical cases who had an “unknown” HIV 
status could possibly have had a mother who was HIV negative and a subsequent ELISA 
done on the mother, hence the actual HIV test not reflecting under the child’s details. Or, 
the attending unit on call did not include an HIV test in their initial workup due to human 
error. The two trauma cases that were also of HIV “unknown” statuses are probably due 
to the trauma unit not requiring a mandatory HIV test on admission.  
 
4.3 Admission Diagnoses 
Admission diagnoses ranged across medical, surgical and trauma cases. Lower 
respiratory tract infections (LRTI) were shown to be the most common diagnosis among 
children with fungal nosocomial sepsis. A possible reason for patients with a LRTI 
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developing nosocomial fungal sepsis could be the prolonged stay in PICU due to their 
dependence on mechanical ventilation. The combination of prolonged exposure to 
nosocomial pathogens and contact with endotracheal tubing could form favourable 
conditions for the colonization and subsequent infection of nosocomial fungal pathogens  
(34). 
 
Following LRTI’s, haematology-oncology (18%) and acute gastroenteritis cases (18%) 
accounted for the second most common conditions with candidaemia. Similarly, an 
epidemiological study in Turkey also showed haematological malignancy as the second-
most common underlying diagnosis.  (24) 
 
4.4 Organisms 
C.albicans have accounted for the majority of Candida isolates among children during 
the 1990’s and early 2000. (25-27,31) However from the mid 2000’s an emergence of 
non-Candida albicans species, particularly C. parapsilosis was observed  (89,90). These 
findings are similar to a Mexican study conducted in 2003 where C. parapsilosis 
attributed 52% in the pediatric population  (90). This trend was also noted in a Spanish 
study  showing a higher percentage of nosocomial infections due to C. parapsilosis 
(47%) and 37% due to C. albicans  (62).Similarly, our study found C.parapsilosis as the 
predominant organism (53%) causing nosocomial fungal sepsis, followed by C. albicans 
(41%).   
This rise in C.parapsilosis isolates can be attributed to three possible reasons. Firstly, 
poor infection control remains a major factor contributing to the spread of C. parapsilosis 
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despite the institution of ICU infection control programmes  (24,91). An American study 
showed poor hand hygiene as an emerging cause of C.parapsilosis outbreaks in the 
neonatal ICU  (91).  Secondly, the organisms’ ability to form biofilms in glucose 
containing media (eg. Parenteral nutrition)  as well as its high propensity to adhere to 
medical devices may enhance its proliferation and survival in the human host in the PICU 
setting, where parenteral nutrition and intravascular catheters and other exogenous 
devices are common place. (34). Lastly, with the advent of newer techniques aiding in 
Candida species differentiation, the isolation of C. parapsilosis using CHROMagar ® has 
become more feasible (26,	  36,	  82) 
 
4.5 Organism Susceptibility 
Antifungal susceptibility and resistance patterns were documented in this study. This is 
the first study to provide this information in a local setting, thus allowing for improved 
empiric prescription in the PICU. Six of the 15 (40%) organisms showed susceptibility to 
fluconazole. This is strikingly different from an Iranian study, which showed 96.6% 
susceptibility to fluconazole  (76).  Additionally, this Iranian study showed both C. 
albicans and C. parapsilosis equally susceptible to fluconazole  (76). However, our 
results showed the majority of isolates susceptible to fluconazole were C. albicans (67%).  
 
In the C. parapsilosis group, a higher proportion was sensitive to voriconazole (67%) as 
opposed to fluconazole (22%). This is interesting of note as the unit’s policy is to initiate 
fluconazole for suspected or proven fungal sepsis. Fluconazole is regarded as a 
favourable option as it is effective against most Candida species, has a low side-effect 
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profile and is also a cost-effective therapy  (92). With the risk of fluconazole resistance 
among non-Candida albicans species, together with the higher incidence of C. 
parapsilosis in the CHBAH PICU, future policy recommendations could possibly be 
open for discussion within the unit  (93). In view of these local findings, the initiation of 
voriconazole, instead of fluconazole could be a future recommendation in the empiric 
treatment of suspected nosocomial fungal sepsis at CHBAH PICU.  However, in lieu of 
the small number of subjects, more research is needed in this field and prospective 
studies with a larger sample size are needed to confirm these findings. 
 
4.6 ICU factors 
Central venous catheters (CVC) were found in all the patients included in the study and 
arterial lines in 70% of patients with candidaemias. The CVC findings support the study 
done by Zaoutis et al, presenting CVC to be an independent risk factor for the 
development of candidaemia in PICU  (27). A Turkish study in 2011 also found patients 
with candidaemia had higher rates of CVC.  (87) A retrospective analysis in 2012 showed 
an alarming 23-fold increase in mortality due to failure of CVC removal.  (59) Given that 
the placement of invasive vascular catheters is usually necessary in ICU patients, these 
findings emphasize the need for timely removal of such devices as a means to minimize 
the potential risk of nosocomial infections. 
 
Furthermore, an American study showed a strong statistical significance between CVC’s 
and C. parapsilosis  (84). Central venous catheters introduce a portal of entry into the 
main vascular system and thus aiding the colonization and growth of opportunistic 
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infections  (27). The placement of invasive catheters (CVC specifically) is routine in all 
patients admitted to PICU at CHBAH. It should be emphasized that their placement be 
performed under strictly sterile conditions, as their placement in critically ill patients 
poses a great risk in developing candidaemia.  (27) 
 
Among the ICU procedure category, mechanical ventilation also featured significantly in 
the study. Eighty-two percent of patients with nosocomial fungal sepsis were on 
mechanical ventilation. These findings are much higher than an American study showing 
37% mechanically ventilated children (411 of 1118 hospitalized paediatric patients) who 
developed a nosocomial fungal infection. (27) A possible reason could be due to the 
limited resources and availability of ICU beds in South Africa, compared to first-world 
countries. This shortage means that patients who should be admitted earlier to PICU are 
kept in high care areas where treatment and ventilation may be sub-optimal, while 
awaiting an ICU bed. This delay could compromise the patient, resulting in a more severe 
phenotype of the presenting condition and possibly the development of a greater number 
of complications, which would thus necessitate a longer PICU stay. 
 
Mechanical ventilation has been shown to be associated with candidaemia.  (59,94) A 
case-control study showed a higher rate of mechanical ventilation in the candidaemia 
group.  (94) Furthermore, Karadag-Oncel et al reported a 7.4-fold increased risk of 
mortality with candidaemia in mechanically ventilated patients.  (59) 
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Lack of resources could also contribute to poor hygiene of equipment, re-usage of 
ventilation tubing and poor hand-washing contributing to prolonged ventilation. This 
study did not investigate how long it took for ventilated patients to develop nosocomial 
fungal sepsis so correlations between exposure and illness could not be drawn. 
 
Corticosteroid usage has been described as a risk factor for nosocomial fungal sepsis  
(27,31,95). This has been hypothesized to the modulation of the immune system by 
corticosteroid therapy, crippling the patient’s ability to prevent dissemination of candida 
infections  (95). Almost half of the subjects in this study (47%) were documented to be 
on corticosteroid therapy at the time of nosocomial sepsis. However, the duration was not 
documented therefore no correlation between duration of treatment and development of 
nosocomial infections could be made.  
 
Hyperalimentation has also been shown to be a suitable environment for the growth of 
Candida owing to its high glucose content  (34). This study showed 35% of patients with 
a nosocomial fungal infection to have been on TPN. These findings are similar to Zaoutis 
et al’s study mentioned above showing 33% of their patients having received 
hyperalimentation.  (27) An American study showed exposure of parenteral nutrition for 
12 days to be a risk factor for potential candidaemia in hospitalized patients . (26) Once 
again, the duration of exposure was not captured in this study so results from the 
aforementioned study could not be compared. 
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Broad-spectrum antibiotic use has been described as a risk factor for the development of 
nosocomial fungal sepsis  (24,27,95). Antibiotic use has been shown to eliminate normal 
flora and thus encourage the colonization and growth of nosocomial organisms  (96). 
This current study documented those patients who had received more than 24 hours of 
antibiotics and what class they had been on. Unfortunately the total duration of antibiotic 
exposure was not investigated so no comment regarding prolonged antibiotic use could 
be made.  
 
In this study, the most frequently used antibiotic in the CHBAH PICU was of the 
penicillin group (71%). This high percentage of penicillin use could account for 
CHBAH’s practice of prescribing either:  ampicillin as the first-line antimicrobial for new 
admissions; or piperacillin-tazobactam used as a second-line option for a suspected 
nosocomial sepsis in the general paediatric ward. An American study found that patients 
receiving 3 or more days of vancomycin or an antimicrobial with anaerobic cover 
(piperacillin-tazobactam, Carbapenem, ceftriaxone, metronidazole, clindamycin etc), 
were independently associated with the development of nosocomial candidaemia in the 
PICU  (61). Based on these findings, patients who are receiving piperacillin-tazobactam 
in CHBAH PICU should not be prescribed more than 3 days unless a specific indication 
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4.7 Potential limitations of the study 
This study has potential limitations. As this study was a retrospective review of records, 
recruitment of patients relied solely on the adequacy of records. Many potential 
candidates were excluded from the study due to inadequate or absent records.  
The lack of a control group was a great limitation in this study. Having a control group 
would have been beneficial as a comparison to substantiate and investigate further the 
associated risk factors in this study. 
The small sample size made it difficult to find significant relationships within the data. 
This small sample size could also give a false representation of patient distribution.  
The data collection tool did not include duration of treatment such as corticosteroids, 
antimicrobials, ventilation etc. These factors could have assisted in exploring the 
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5.0 CONCLUSION 
 
This study is the first in South Africa investigating factors associated with nosocomial 
fungal sepsis at CHBAH PICU. The incidence is higher than what has been reported in 
some other studies. The majority of patients were less than a year of age and all the 
patients had CVC’s. However this might have been due to the fact that it is a general 
practice for the unit to routinely insert CVC’s. Although there was a predominance of C. 
parapsilosis that is susceptible to voriconazole, the study sample size was small and this 
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APPENDIX A – REFERENCE VALUES 
 
 





(leukocytes x 103/mm) 
0 days to 1 
wk 
> 180 > 50 > 34 
1 wk to 1 mo > 180 > 40 > 19.5 or < 5 
1 mo to 1 yr > 180 > 34 > 17.5 or < 5 
2-5 yrs > 140 > 22 >15.5 or < 6 
6-12 yrs > 130 > 18 > 13.5 or < 4.5 
13 to <18 yrs > 110 > 14 > 11 or <4.5 
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APPENDIX B- DATA COLLECTION TOOL 
 
 
STUDY NO:  
 
Demographics: 
Age       __yr  __mo 
Gender:   M□ F□ 
HIV status:  Pos □ Neg□ 
 
Background: 
DOA:   __/__/__ 
Date of Sepsis:  __/__/__ 
Pre-ICU major op: Y□ N□ 
Primary Condition: __________ 
Blood culture:  __________ 





CVC:   Y□ N□ 
A-line:   Y□ N□ 
Chest Drain:  Y□ N□ 
Tracheostomy:  Y□ N□ 
Antibiotic classes (given ≥24 hrs): 
! Penicillin Y□ N□ 
! Cephalosporin Y□ N□ 
! Aminoglyc Y□ N□ 
! Carbapenem Y□ N□ 
! Glycopepep Y□ N□ 
! Antifungal Y□ N□ 
! TMX  Y□ N□ 
! Rifampicin Y□ N□  
! Metronidazole Y□ N□ 
Haemodialysis  Y□ N□ 
Peritoneal dialysis Y□ N□ 
Mechanical vent  Y□ N□ 
Immunosuppres  Y□ N□ 
Multip Transfu Y□ N□ 
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